Gynoconazol vaginal cream and suppositories

Gynoconazol vaginal cream and suppositories composition:

Gynoconazol 0.4% vaginal cream: contains 0.4% of the antifungal agent terconazole.
Gynoconazol 0.8% vaginal cream: contains 0.8% of the antifungal agent terconazole.
Gynoconazol 80 vaginal suppository: contains
80 mg of the antifungal agent terconazole

Gynoconazol vaginal cream and suppositories clinical pharmacology:

Terconazole exhibits fungicidal activity in vitro against candida albicans. Antifungal activity has also been demonstrated againsl.QtlJ.er fungi.
Lactobacillus spp., beneficial bacteria found in the human vagina, are not affected by terconazole treatment. Terconazole may exert its antifungal activity by the disruption of normal fungal cell membrane permeability. No resistance to terconazole has developed during successive passages of candida albicans.

Gynoconazol vaginal cream and suppositories indications:

Gynoconazol 0.4% Vaginal cream is indicated for the local treatment of vulvovaginal candidiasis (monilliasis). Activity also has been demonstrated against other fungi. Gynoconazol 0.8% Vaginal cream and Gynoconazol 80 vaginal suppository are indicated for the local treatment & prophylaxis of vulvovaginal candidiasis (monilliasis) activity as well as other fungi.

Gynoconazol vaginal cream and suppositories side effects :

Side effects are rare & mild in most cases. Most frequently reported were local irritation, pruritis & burning sensation especially at the start of the treatment. Complaints of abdominal pain, fever & skin rash have been reported.

Gynoconazol vaginal cream and suppositories warnings:

None.

Gynoconazol vaginal cream and suppositories precautions:

The treatment should be discontinued if local irritation reaction, fever or chills occurred. General hygienic measures should be observed to control sources of infection & re-infection. Appropriate therapy is indicated if the sexual partner is also infected.

Gynoconazol vaginal cream and suppositories during pregnancy and lactation :

There are no adequate and controlled studies to date using intravaginal terconazole in women during the first trimester of pregnancy. The drug has been used intravaginally during the second and third trimester of pregnancy without adverse effects on the outcome of pregnancy. However, the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.